Form 4: Neogenomics Executive Warren Stone Reports Stock Transactions
SEC Form 4 Filing
Warren Stone, President & Chief Operating Officer of Neogenomics, reports the release of restricted stock units and associated tax withholding, along with details of stock options and restricted stock units granted.
Summary
- On May 2, 2025, Warren Stone, President & Chief Operating Officer of Neogenomics, filed a Form 4.
- The filing reports the release of 5,969 restricted stock units, which convert to common stock upon vesting.
- 1,454 shares were disposed of to cover tax obligations related to the release of restricted stock units.
- Following these transactions, Stone directly owns 95,308 shares of common stock.
- The filing also details various stock options and restricted stock units previously granted to Stone, with vesting schedules and exercise prices.
- Modifications to vesting schedules were made in connection with Stone's promotion to President & Chief Operating Officer on April 1, 2025, for options and restricted stock units granted on February 21, 2025.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing detailing executive stock transactions. It doesn't contain any particularly positive or negative information, hence a neutral sentiment score.
Positives
- The document provides transparency into executive compensation and stock ownership.
- The vesting schedules of stock options and restricted stock units are clearly outlined.
- The modification of vesting schedules in connection with Stone's promotion aligns incentives with his new role.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are closely monitored by investors for insights into management's confidence in the company's future prospects.
Comparison to Industry Standards
- Executive compensation packages, including stock options and restricted stock units, are standard practice in the biotechnology and diagnostics industries.
- Companies like Exact Sciences and Guardant Health also utilize stock-based compensation to incentivize their executives.
- The vesting schedules and performance-based criteria outlined in the document are typical for executive equity grants in similar companies.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President & Chief Operating Officer | NA | Warren Stone | 04/01/2025 | Promotion |
Stakeholder Impact
- Shareholders may be interested in the details of executive compensation and stock ownership.
- Employees may be impacted by the company's overall financial performance, which is indirectly linked to executive incentives.
Key Dates
| Date | Description |
|---|---|
| 12/01/2022 | Mr. Stone was granted 166,113 stock options. |
| 05/11/2023 | Mr. Stone was granted 53,969 stock options and 28,838 restricted stock units. |
| 02/23/2024 | Mr. Stone was granted 42,344 stock options, 25,329 restricted stock units, and 25,330 performance stock units. |
| 05/02/2024 | Mr. Stone was granted 29,976 stock options, 17,905 restricted stock units, and 17,908 performance stock units. |
| 02/21/2025 | Mr. Stone was granted 143,266 stock options and 84,317 restricted stock units. |
| 04/01/2025 | Mr. Stone was promoted to President & Chief Operating Officer, and vesting schedules were modified. Mr. Stone was also granted 94,518 stock options and 52,687 restricted stock units. |
| 05/02/2025 | Date of the reported transactions: release of restricted stock units and tax withholding. |
| 05/06/2025 | Date of the Form 4 filing. |
| 05/11/2026 | Expiration date for performance stock units granted on May 11, 2023. |
| 02/23/2027 | Expiration date for performance stock units granted on February 23, 2024. |
| 05/02/2027 | Expiration date for performance stock units granted on May 2, 2024. |
| 12/01/2029 | Expiration date for stock options granted on December 1, 2022. |
| 05/11/2030 | Expiration date for stock options granted on May 11, 2023. |
| 02/23/2034 | Expiration date for stock options granted on February 23, 2024. |
| 05/02/2034 | Expiration date for stock options granted on May 2, 2024. |
| 02/21/2035 | Expiration date for stock options granted on February 21, 2025. |
| 04/01/2035 | Expiration date for stock options granted on April 1, 2025. |
Keywords
Form 4, Neogenomics, Warren Stone, Stock Options, Restricted Stock Units, Executive Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.